 Abstract, TPPLND is a new drug developed to enhance the effectiveness of radiotherapy. It works by targeting mitochondria and blocking the production of ATP, thus creating a hypoxic environment within cancer cells. This hypoxic environment causes increased DNA damage, which makes the cancer cells more sensitive to radiation therapy. Additionally, TPPLND also blocks the expression of PD-L1, which further increases the effectiveness of radiotherapy. This article was authored by Sai Jun-Won, Zygon Zhou, Rui Hu, and others.